Rankia España Rankia Argentina Rankia Argentina Rankia Chile Rankia Chile Rankia Colombia Rankia Colombia Rankia México Rankia México Rankia Perú Rankia Perú Rankia Portugal Rankia Portugal Rankia USA Rankia USA
Acceder

Farmas USA

123K respuestas
Farmas USA
44
suscriptores
Farmas USA
Página
15.296 / 15.382
#122361

Re: Farmas USA

Liones
Siento no poder acompañaros con ésta. No la tienen en ING, la solicité hace más de una semana pero se ve que la cosa va despacio. Suerte
KPTI
5 recomendaciones
#122362

Re: Farmas USA

anaramos
KPTI

Pues qué suerte. Yo tenía una entrada en 17,89, que obviamente no ha entrado.

He mirado los institucionales. Superan el 100%.

«Después de nada, o después de todo/ supe que todo no era más que nada.»

7 recomendaciones
#122364

Re: Farmas USA

anaramos
ARNA

Datos de la colocación final: 50$ por acción. 5.500.000 ampliables con 820.000 más.

«Después de nada, o después de todo/ supe que todo no era más que nada.»

5 recomendaciones
#122365

Re: Farmas USA

Cosmo
PHAS vendidas a 5.95$ las compradas a 3,60€ compradas en la debacle, +70% aprox
10 recomendaciones
#122367

Re: Farmas USA

anaramos
KPTI

Karyopharm up 6% on late-stage selinexor data in multiple myeloma


Datos conocidos ya. Aportan detalle.


  • Karyopharm Therapeutics (NASDAQ:KPTI) announces detailed results from a Phase 3 clinical trial, BOSTON, evaluating Xpovio (selinexor), combined with Takeda's Velcade (bortezomib) and low-dose dexamethasone, in multiple myeloma patients who had received one-to-three prior lines of therapy. The data will be virtually presented tomorrow at the ASCO Scientific Program.
  • The selinexor triplet therapy, dosed weekly, resulted in a 47% increase in median progression-free survival (PFS) compared to Velcade + dexamethasone (Vd) dosed twice weekly. The effect was consistent across a range of patient subgroups such as those previously treated with lenalidomide (Bristol Myers Squibb's Revlimid) and those with high-risk chromosomal profiles. Specifically, median PFS in the selinexor arm was 13.9 months versus 9.5 months in the Vd arm (p=0.0075).
  • The overall response rate in the selinexor arm was also superior to the Vd arm (76.4% vs. 62.3%; p=0.0012).
  • Median overall survival (OS) in the selinexor arm was not reached at data cutoff. Median OS in the Vd arm was 25.0 months.
  • On the safety front, the rate of peripheral neuropathy was lower in the selinexor arm (32.3% vs. 47.1%; p=0.0010).
  • The company has submitted a supplemental marketing application to the FDA for the triplet therapy in treatment-experienced multiple myeloma patients. It expects to file an application in Europe later this year.

«Después de nada, o después de todo/ supe que todo no era más que nada.»

9 recomendaciones
#122368

Re: Farmas USA

anaramos
KPTI

Esta noticia influiría más en un subidón del precio que la anterior, pero no parece demasiado a la vista de nadie aún:

3 pacientes con COViD que han tomado el fármaco han salido andando del hospital.

Doctors at Roper ‘encouraged’ by early results in COVID-19 treatment trials


The hospital is currently conducting two official trials, one using plasma from recovered COVID-19 patients and the other administering a cancer drug, Selinexor, to combat the virus.
Stock says three patients have taken part in the drug trial.

“Each patient that has received the drug has actually been discharged from the hospital,” Stock said. “So if you look at outcome, at least we can say anecdotally that it seems to be at least not hindering their ability to recover from this infection and ultimately get well.”

«Después de nada, o después de todo/ supe que todo no era más que nada.»

10 recomendaciones
Brokers destacados
Este sitio web usa cookies para analizar la navegación del usuario. Política de cookies.
Cerrar